Detalle Publicación

ARTÍCULO
Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer ROSiA single-arm phase 3B study
Autores: Oza, Amit M.; Selle, Frederic; Davidenko, Irina; Korach, Jacob; Mendiola, Cesar; Pautier, Patricia; Chmielowska, Ewa; Bamias, Aristotelis; DeCensi, Andrea; Zvirbule, Zanete; González Martín, Antonio; Hegg, Roberto; Joly, Florence; Zamagni, Claudio; Gadducci, Angiolo; Martin, Nicolas; Robb, Stephen; Colombo, Nicoletta
Título de la revista: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
ISSN: 1525-1438
Volumen: 27
Número: 1
Páginas: 50-58
Fecha de publicación: 2017
Resumen:
Extended bevacizumab demonstrated increased incidences of proteinuria and hypertension compared with 12 or 15 months of bevacizumab in previous trials, but these rarely led to bevacizumab discontinuation. Median PFS is the longest reported for frontline bevacizumab-containing therapy. The longer bevacizumab duration beyond 15 months in this study may improve PFS without substantially compromising safety.